Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 32, 2017, Pages E6613-E6622

  Nikolaidis, Nikolaos M ^a   Noel, John G ^b   Pitstick, Lori B ^a   Gardner, Jason C ^a,b   Uehara, Yasuaki ^a   Wu, Huixing ^a   Saito, Atsushi ^a,d   Lewnard, Kara E ^a   Liu, Huan ^a   White, Mitchell R ^c   Hartshorn, Kevan L ^c   McCormack, Francis X ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alveolar epithelial type II; Influenza A; Mitogen; mTOR; Viral pneumonia

Indexed keywords

CYTOKINE; KERATINOCYTE GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; VIRUS NUCLEOPROTEIN; FGF7 PROTEIN, MOUSE; MITOGENIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EX VIVO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA A VIRUS; LUNG ALVEOLUS CELL TYPE 2; LUNG PARENCHYMA; MITOGENESIS; MOLECULAR BIOLOGY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; VIRUS PATHOGENESIS; VIRUS PNEUMONIA; ANIMAL; CHEMICALLY INDUCED; DBA MOUSE; DISEASE PREDISPOSITION; FEMALE; LUNG ALVEOLUS EPITHELIUM CELL; METABOLISM; ORTHOMYXOVIRUS INFECTION; PATHOLOGY;

ALVEOLAR EPITHELIAL CELLS; ANIMALS; CELL PROLIFERATION; DISEASE SUSCEPTIBILITY; FEMALE; FIBROBLAST GROWTH FACTOR 7; INFLUENZA A VIRUS; MICE; MICE, INBRED DBA; MITOGENS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 85026889035     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1621172114     Document Type: Article

References (54)

1. Crowther JE, et al. (2004) Pulmonary surfactant protein a inhibits macrophage reactive oxygen intermediate production in response to stimuli by reducing NADPH oxidase activity. J Immunol 172:6866–6874.
2. Zhou H, et al. (2012) Hospitalizations associated with influenza and respiratory syn-cytial virus in the United States, 1993-2008. Clin Infect Dis 54:1427–1436.
3. Russell CA, et al. (2008) The global circulation of seasonal influenza A (H3N2) viruses. Science 320:340–346.
4. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J (2000) Clinical signs and symptoms predicting influenza infection. Arch Intern Med 160:3243–3247.
5. Short KR, Kroeze EJ, Fouchier RA, Kuiken T (2014) Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 14:57–69.
6. Kourtis AP, Read JS, Jamieson DJ (2014) Pregnancy and infection. N Engl J Med 371:1077.
7. Centers for Disease Control and Prevention (CDC) (2010) Estimates of deaths associated with seasonal influenza — United States, 1976-2007. MMWR Morb Mortal Wkly Rep 59:1057–1062.
8. Murin S, Bilello KS (2005) Respiratory tract infections: Another reason not to smoke. Cleve Clin J Med 72:916–920.
9. Myles PR, et al.; Influenza Clinical Information Network (FLU-CIN) (2012) Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax 67:709–717.
10. Liang Y, et al. (2014) PM2.5 in Beijing - temporal pattern and its association with influenza. Environ Health 13:102.
11. Hilleman MR (2002) Realities and enigmas of human viral influenza: Pathogenesis, epidemiology and control. Vaccine 20:3068–3087.
12. Whitley RJ, Monto AS (2006) Prevention and treatment of influenza in high-risk groups: Children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 194:S133–S138.
13. Bouvier NM, Palese P (2008) The biology of influenza viruses. Vaccine 26:D49–D53.
14. Steinhauer DA (1999) Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 258:1–20.
15. Cros JF, Palese P (2003) Trafficking of viral genomic RNA into and out of the nucleus: Influenza, Thogoto and Borna disease viruses. Virus Res 95:3–12.
16. Kash JC, Goodman AG, Korth MJ, Katze MG (2006) Hijacking of the host-cell response and translational control during influenza virus infection. Virus Res 119:111–120.
17. Nayak DP, Hui EK, Barman S (2004) Assembly and budding of influenza virus. Virus Res 106:147–165.
18. Wagner R, Matrosovich M, Klenk HD (2002) Functional balance between haemag-glutinin and neuraminidase in influenza virus infections. Rev Med Virol 12:159–166.
19. LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T (2002) Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol 282:L563–L572.
20. Crouch E, et al. (2011) Mutagenesis of surfactant protein D informed by evolution and x-ray crystallography enhances defenses against influenza A virus in vivo. J Biol Chem 286:40681–40692.
21. Li G, et al. (2002) Surfactant protein-A–deficient mice display an exaggerated early inflammatory response to a beta-resistant strain of influenza A virus. Am J Respir Cell Mol Biol 26:277–282.
22. Hawgood S, et al. (2004) Pulmonary collectins modulate strain-specific influenza a virus infection and host responses. J Virol 78:8565–8572.
23. Vigerust DJ, et al. (2007) N-linked glycosylation attenuates H3N2 influenza viruses. J Virol 81:8593–8600.
24. LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR (2001) Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 167:5868–5873.
25. Barazzone C, et al. (1999) Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol 154:1479–1487.
26. Guo J, et al. (1998) Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am J Physiol 275:L800–L805.
27. Deterding RR, et al. (1997) Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor. Proc Assoc Am Physicians 109:254–268.
28. Yano T, Deterding RR, Simonet WS, Shannon JM, Mason RJ (1996) Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol 15:433–442.
29. Panos RJ, Bak PM, Simonet WS, Rubin JS, Smith LJ (1995) Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J Clin Invest 96:2026–2033.
30. Wu H, Suzuki T, Carey B, Trapnell BC, McCormack FX (2011) Keratinocyte growth factor augments pulmonary innate immunity through epithelium-driven, GM-CSF-dependent paracrine activation of alveolar macrophages. J Biol Chem 286:14932–14940.
31. Gardner JC, et al. (2016) Keratinocyte growth factor supports pulmonary innate immune defense through maintenance of alveolar antimicrobial protein levels and macrophage function. Am J Physiol Lung Cell Mol Physiol 310:L868–L879.
32. Guagnano V, et al. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 54:7066–7083.
33. Weinheimer VK, et al. (2012) Influenza A viruses target type II pneumocytes in the human lung. J Infect Dis 206:1685–1694.
34. van Riel D, et al. (2006) H5N1 virus attachment to lower respiratory tract. Science 312:399.
35. van Riel D, et al. (2007) Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol 171:1215–1223.
36. Shinya K, et al. (2006) Avian flu: Influenza virus receptors in the human airway. Nature 440:435–436.
37. Kumar PA, et al. (2011) Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell 147:525–538.
38. Hofer CC, Woods PS, Davis IC (2015) Infection of mice with influenza A/WSN/33 (H1N1) virus alters alveolar type II cell phenotype. Am J Physiol Lung Cell Mol Physiol 2015;308:L628–L638.
39. Taubenberger JK, Morens DM (2008) The pathology of influenza virus infections. Annu Rev Pathol 3:499–522.
40. Tripathi S, White MR, Hartshorn KL (2015) The amazing innate immune response to influenza A virus infection. Innate Immun 21:73–98.
41. Wang CH, et al. (2014) Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med 42:313–321.
42. König R, et al. (2010) Human host factors required for influenza virus replication. Nature 463:813–817.
43. Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C (2010) The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog 6:e1001099.
44. Hale BG, Jackson D, Chen YH, Lamb RA, Randall RE (2006) Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. Proc Natl Acad Sci USA 103:14194–14199.
45. Ehrhardt C, et al. (2006) Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol 8:1336–1348.
46. Sawicki L, Baron S, Isaacs A (1961) Influence of increased oxygenation on influenza virus infection in mice. Lancet 2:680–682.
47. Adamson IY, Bowden DH (1974) The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen. Lab Invest 30: 35–42.
48. Evans MJ, Hackney JD (1972) Cell proliferation in lungs of mice exposed to elevated concentrations of oxygen. Aerosp Med 43:620–622.
49. Kauffman SL (1980) Cell proliferation in the mammalian lung. Int Rev Exp Pathol 22: 131–191.
50. Kark JD, Lebiush M (1981) Smoking and epidemic influenza-like illness in female military recruits: A brief survey. Am J Public Health 71:530–532.
51. Kark JD, Lebiush M, Rannon L (1982) Cigarette smoking as a risk factor for epidemic a(h1n1) influenza in young men. N Engl J Med 307:1042–1046.
52. Wells AB, Lamerton LF (1975) Regenerative response of the rat tracheal epithelium after acute exposure to tobacco smoke: A quantitative study. J Natl Cancer Inst 55: 887–891.
53. Spielberger R, et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598.
54. Schroeder T, Zohren F, Saure C, Kobbe G, Haas R (2009) Palifermin, a recombinant human keratinocyte growth factor, triggers reactivation of anogenital human papillomavirus infection in a HIV-positive patient with diffuse large cell B-cell non-Hodgkin lymphoma. Bone Marrow Transplant 44:823–824.